Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 3, 2009, Pages 253-257

  Billups, Sarah J ^a,b   Delate, Thomas ^a   Dugan, Daniel ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

Drug interactions; Drug toxicity; Selective serotonin reuptake inhibitors; Therapeutic drug monitoring; Tricyclic antidepressants

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; BLOOD; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG INTERACTION; DRUG MONITORING; METABOLISM; MIDDLE AGED;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUPROPION; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; PAROXETINE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 65249112850     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1697     Document Type: Article

References (12)

1. Berger A, Dukes E, Edelsberg J, et al. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clinical J Pain 2007; 23: 251-258. DOI: 10.1097/AJp. 0b013e31802f67dd
2. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7: 51-54. DOI: 10.1007/s11916-003-0010-8
3. Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem 1988; 34: 822-828.
4. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. Clin Pharmacokinet 1999; 37: 147-165. DOI: 10.2165/ 00003088-199937020-00004
5. McManus P, Mant A, Mitchell P, Birkett D, Dudley J. Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? Br J Clin Pharmacol 2001; 51: 93-98.
6. Patten SB, Beck C. Major depression and mental health care utilization in Canada: 1994 to 2000. Can J Psychiatry 2004; 49: 303-309.
7. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6-13. DOI: 1038/ sj.tpj.6500285
8. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-748. DOI: 10.1038/sj.bjp. 0707253
9. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001-1006.
10. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25: 226-229. DOI: 10.1097/01.jcp. 0000162805.46453.e3
11. Patetta M. Exact, conditional, and nominal logistic regression. In Categorical Data Analysis Using Logistic Regression Course Notes. Patetta M (ed.). SAS Institute Inc: Cary, NC, 2005; 523-528.
12. de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 2007; 27: 241-245. DOI: 10.1097/JCp. 0b013e318058244d